<DOC>
	<DOCNO>NCT00012246</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . PURPOSE : Randomized phase II trial compare effectiveness two different vaccine treat patient cancer gastrointestinal tract .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Cancer Gastrointestinal Tract</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether immunization carcinoembryonic antigen ( CEA ) peptide 1-6D ( CAP 1-6D ) emulsify Montanide ISA-51 adjuvant dissolve sargramostim ( GM-CSF ) generate CAP 1-6D-specific T cell patient CEA-producing adenocarcinomas gastrointestinal tract origin . - Determine whether vaccination CAP 1-6D generate cytotoxic T cell CEA-expressing tumor patient . - Determine whether vaccine produce antitumor response patient . - Determine frequency severity toxic effect associate vaccine patient . OUTLINE : This randomize study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive carcinoembryonic antigen peptide 1-6D ( CAP 1-6D ) emulsify Montanide ISA-51 adjuvant subcutaneously day 1 . - Arm II : Patients receive CAP 1-6D dissolve sargramostim ( GM-CSF ) intradermally day 1 . Treatment repeat arm every 3 week 6 course absence disease progression unacceptable toxicity . Patients follow 3 week necessary . PROJECTED ACCRUAL : A total 10-36 patient ( 5-18 per arm ) accrue study within 36 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage II , III , IV adenocarcinoma gastrointestinal tract originate 1 follow : Esophagus Stomach Pancreas Small intestine Colon rectum Gall bladder Extrahepatic bile duct Ampulla Vater Completed standard therapy risk recurrent disease OR relatively stable metastatic disease life expectancy least 6 month Carcinoembryonic antigen ( CEA ) produce tumor evidence detectable blood level CEA positive CEA immunohistochemical stain Human Leukocyte Antigen ( HLA ) A2+ PATIENT CHARACTERISTICS : Age : 18 Performance status : Southwest Oncology Group ( SWOG ) 01 Life expectancy : See Disease Characteristics Hematopoietic : White Blood Count ( WBC ) least 4,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 8 g/dL Hepatic : Serum Glutamic Oxalacetic Transaminase ( SGOT ) Serum Glutamic Pyruvic Transaminase ( SGPT ) great 3 time upper limit normal Hepatitis B C negative Renal : Creatinine great 2.0 mg/dL Other : No prior malignancy unless currently disease free therapy malignancy Early skin cancer allow No AIDS HIV negative Not pregnant nursing Fertile patient must use effective contraception 30 day study participation PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy Chemotherapy : At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy Surgery : At least 4 week since prior surgery Other : No concurrent therapy malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>small intestine adenocarcinoma</keyword>
	<keyword>localize gallbladder cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>localize extrahepatic bile duct cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>recurrent small intestine cancer</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>adenocarcinoma gallbladder</keyword>
	<keyword>adenocarcinoma extrahepatic bile duct</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>